Cargando…

Integrated care in ovarian cancer “IgV Ovar”: results of a German pilot for higher quality in treatment of ovarian cancer

INTRODUCTION: Late-stage ovarian cancer patient’s survival depends on complete cytoreduction and chemotherapy. Complete cytoreduction is more often achieved in institutions with a case volume of >20 cases per year. The Integrated care program Ovar (IgV Ovar) was founded in 2005 and started recrui...

Descripción completa

Detalles Bibliográficos
Autores principales: Keyver-Paik, M.-D., Abramian, A., Domröse, C., Döser, A., Höller, T., Friedrich, M., Meier, W., Menn, K., Kuhn, W.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2015
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4717158/
https://www.ncbi.nlm.nih.gov/pubmed/26498774
http://dx.doi.org/10.1007/s00432-015-2055-6
_version_ 1782410604493930496
author Keyver-Paik, M.-D.
Abramian, A.
Domröse, C.
Döser, A.
Höller, T.
Friedrich, M.
Meier, W.
Menn, K.
Kuhn, W.
author_facet Keyver-Paik, M.-D.
Abramian, A.
Domröse, C.
Döser, A.
Höller, T.
Friedrich, M.
Meier, W.
Menn, K.
Kuhn, W.
author_sort Keyver-Paik, M.-D.
collection PubMed
description INTRODUCTION: Late-stage ovarian cancer patient’s survival depends on complete cytoreduction and chemotherapy. Complete cytoreduction is more often achieved in institutions with a case volume of >20 cases per year. The Integrated care program Ovar (IgV Ovar) was founded in 2005 and started recruiting in 2006 with 21 health insurances and six expert centers of ovarian cancer treatment as a quality initiative. Results of the pilot and outcomes of patients of three participating centers will be presented here. METHODS: Data of 1038 patients with ovarian cancer were collected. Adjuvant patients (n = 505) stage FIGO IIB-IV (n = 307) were analyzed for cytoreduction and survival. FIGO IIIC patients were analyzed separately. RESULTS: Median follow-up was 32.7 months. Progression-free survival (PFS) was 23.1 months and overall survival (OS) was 53.6 months for stage IIB-IV. Patients with FIGO IIIC were completely cytoreduced in 48 %. PFS was 21, 29 months if completely cytoreduced. OS was 47.4, 64.9 months if completely cytoreduced. DISCUSSION: Although the IgV Ovar Rhineland proved to have some structural problems with recruitment and prospective data collection, cytoreduction rates and outcome of patients prove treatment of patients in expert centers is superior to the national and international mean. Therefore, a new quality initiative will be started to bring more awareness to women and to their gynecologists and general practitioners of just how important a good referral strategy is.
format Online
Article
Text
id pubmed-4717158
institution National Center for Biotechnology Information
language English
publishDate 2015
publisher Springer Berlin Heidelberg
record_format MEDLINE/PubMed
spelling pubmed-47171582016-01-25 Integrated care in ovarian cancer “IgV Ovar”: results of a German pilot for higher quality in treatment of ovarian cancer Keyver-Paik, M.-D. Abramian, A. Domröse, C. Döser, A. Höller, T. Friedrich, M. Meier, W. Menn, K. Kuhn, W. J Cancer Res Clin Oncol Original Article – Clinical Oncology INTRODUCTION: Late-stage ovarian cancer patient’s survival depends on complete cytoreduction and chemotherapy. Complete cytoreduction is more often achieved in institutions with a case volume of >20 cases per year. The Integrated care program Ovar (IgV Ovar) was founded in 2005 and started recruiting in 2006 with 21 health insurances and six expert centers of ovarian cancer treatment as a quality initiative. Results of the pilot and outcomes of patients of three participating centers will be presented here. METHODS: Data of 1038 patients with ovarian cancer were collected. Adjuvant patients (n = 505) stage FIGO IIB-IV (n = 307) were analyzed for cytoreduction and survival. FIGO IIIC patients were analyzed separately. RESULTS: Median follow-up was 32.7 months. Progression-free survival (PFS) was 23.1 months and overall survival (OS) was 53.6 months for stage IIB-IV. Patients with FIGO IIIC were completely cytoreduced in 48 %. PFS was 21, 29 months if completely cytoreduced. OS was 47.4, 64.9 months if completely cytoreduced. DISCUSSION: Although the IgV Ovar Rhineland proved to have some structural problems with recruitment and prospective data collection, cytoreduction rates and outcome of patients prove treatment of patients in expert centers is superior to the national and international mean. Therefore, a new quality initiative will be started to bring more awareness to women and to their gynecologists and general practitioners of just how important a good referral strategy is. Springer Berlin Heidelberg 2015-10-23 2016 /pmc/articles/PMC4717158/ /pubmed/26498774 http://dx.doi.org/10.1007/s00432-015-2055-6 Text en © The Author(s) 2015 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.
spellingShingle Original Article – Clinical Oncology
Keyver-Paik, M.-D.
Abramian, A.
Domröse, C.
Döser, A.
Höller, T.
Friedrich, M.
Meier, W.
Menn, K.
Kuhn, W.
Integrated care in ovarian cancer “IgV Ovar”: results of a German pilot for higher quality in treatment of ovarian cancer
title Integrated care in ovarian cancer “IgV Ovar”: results of a German pilot for higher quality in treatment of ovarian cancer
title_full Integrated care in ovarian cancer “IgV Ovar”: results of a German pilot for higher quality in treatment of ovarian cancer
title_fullStr Integrated care in ovarian cancer “IgV Ovar”: results of a German pilot for higher quality in treatment of ovarian cancer
title_full_unstemmed Integrated care in ovarian cancer “IgV Ovar”: results of a German pilot for higher quality in treatment of ovarian cancer
title_short Integrated care in ovarian cancer “IgV Ovar”: results of a German pilot for higher quality in treatment of ovarian cancer
title_sort integrated care in ovarian cancer “igv ovar”: results of a german pilot for higher quality in treatment of ovarian cancer
topic Original Article – Clinical Oncology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4717158/
https://www.ncbi.nlm.nih.gov/pubmed/26498774
http://dx.doi.org/10.1007/s00432-015-2055-6
work_keys_str_mv AT keyverpaikmd integratedcareinovariancancerigvovarresultsofagermanpilotforhigherqualityintreatmentofovariancancer
AT abramiana integratedcareinovariancancerigvovarresultsofagermanpilotforhigherqualityintreatmentofovariancancer
AT domrosec integratedcareinovariancancerigvovarresultsofagermanpilotforhigherqualityintreatmentofovariancancer
AT dosera integratedcareinovariancancerigvovarresultsofagermanpilotforhigherqualityintreatmentofovariancancer
AT hollert integratedcareinovariancancerigvovarresultsofagermanpilotforhigherqualityintreatmentofovariancancer
AT friedrichm integratedcareinovariancancerigvovarresultsofagermanpilotforhigherqualityintreatmentofovariancancer
AT meierw integratedcareinovariancancerigvovarresultsofagermanpilotforhigherqualityintreatmentofovariancancer
AT mennk integratedcareinovariancancerigvovarresultsofagermanpilotforhigherqualityintreatmentofovariancancer
AT kuhnw integratedcareinovariancancerigvovarresultsofagermanpilotforhigherqualityintreatmentofovariancancer